Pharmaceutical care for patients with G6PD deficiency

Historically, G6PD deficiency was reported for the first time in individuals who received doses of primaquine, primary drug to be addressed study, treat malaria, and triggered a symptomatic response with jaundice hematological field erythroenzymopathies. In this sense, through an integrative review, present research aimed discuss importance pharmaceutical care its relationship treatment patients G6DP enzyme deficiency. Glucose-6-phosphate dehydrogenase (G6PD) is common prevalent many malaria-endemic countries. are susceptible hemolysis during oxidative stress, which can occur from exposure certain drugs, including 8-aminoquinolines used Plasmodium vivax malaria. way, would become tool monitoring managing problems that may pharmacotherapy. Guiding, educating implementing quantitative mechanisms diagnosing providing adequate radical cure heterozygous women, remain at risk hemolysis.